News
-
-
PRESS RELEASE
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
MIRA Pharmaceuticals, Inc. announces Phase 1 clinical trial initiation for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain, in Israel. Study aims to evaluate safety, tolerability, and pharmacokinetics -
-
PRESS RELEASE
Brenmiller Energy Can Help Turn The EU's Clean Industry Deal Vision Into Tangible Reality
The European Commission introduces the Clean Industrial Deal (CID) - a feasible solution for Europe's energy crisis and decarbonization needs, highlighted by Brenmiller Energy's innovative bGen™ thermal energy storage system -
PRESS RELEASE
Focus Impact BH3 Stockholders Vote to Approve Business Combination with XCF Global Capital, Inc.
Focus Impact BH3 Acquisition Company and XCF Global Capital announce stockholder approval for Business Combination with XCF, paving the way for listing on Nasdaq Capital Market under ticker symbol SAFX -
PRESS RELEASE
EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum
CompuGroup Medical SE & Co. KGaA plans to reduce 2024 dividend to legal minimum of EUR 0.05 per share, citing long-term growth focus and financial performance -
-
-
PRESS RELEASE
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tharimmune, Inc. expands product pipeline with HS1940, a multispecific biologic targeting PD-1 and VEGF epitopes to enhance cancer treatment options. EpiClick™ Technology enables creation of novel therapeutics -
PRESS RELEASE
Nepra Foods Reports Q3 2025 Financials With Revenue Growth and Enhanced Margins
Nepra Foods Inc. reports strong financial performance in Q3 2025, with revenue surge, gross margin growth, expense reduction, and narrowed net loss. Strategic advances position the company well in the gluten-free market
